Sechenov University, one of Russia’s leading research universities, and the biopharmaceutical company NANOLEK have entered into a strategic and technological partnership to develop immunobiological medicines.
Among other things, the parties have agreed to work together on a range of cutting-edge medicines that can compete on global markets by being innovative and technologically advanced.
The intellectual and technology capacity of the joint partnership will cover the entire cycle of immunobiological drug development; this will include vaccines, fr om drug concept development to finished products and pre-clinical trials.
At BIOTECHMED 2020 Forum, Health Minister Mikhail Murashko said that science, practical skills and production would have to co-exist in the country so as to secure the advancement of new technologies.
The cooperation will be the first step in a partnership between the fundamental sciences and advanced industry at a successful scale.
Petr Glybochko, Rector of Sechenov University, RAS Academician, “Sechenov University is on its way to becoming a world-class university, with a focus on multidisciplinary education, research and bringing developments into healthcare practice. We build on our competencies by creating innovative medicines, contributing to the quality of life and health of people, and to the economic empowerment of the country through access to export markets. It is now that cooperation between Sechenov University and NANOLEK takes on particular relevance. The pandemic has made us aware of the very real biological threats and has highlighted the need to get prepared for them in advance. It has become clear that the success of this challenge requires an interplay of science and industry, along with a willingness to digitise medicine and industry.”
Vladimir Khristenko, President of NANOLEK, “The joint efforts of our colleagues at Sechenov University and NANOLEK will, I am sure, make it possible to reach a new level of interaction between science and industry very quickly. Our collaborative project fits perfectly into the concept for the 2035 Infectious Diseases Immunoprophylaxis Strategy approved in late September. Science is going ahead very rapidly, and the entire scientific and production capacity must be deployed to achieve the objectives outlined in the strategy. NANOLEK has biotechnology competencies and strong production capacity under GMP standards wh ere fully domestic, innovative immunobiological medicines can be produced.”
About Sechenov University
Sechenov University is a centre of academic, scientific and resource excellence in Russia’s healthcare system and is training future leaders in national and international healthcare. The mission it pursues is to create favourable climate for medical education and science to secure Russia’s rightful place in the global healthcare system. The University provides a full cycle of educational programmes for the most talented students internationally. It is a leader when it comes to creating and implementing effective multidisciplinary medical education models and methodologies. It trains qualified medical personnel for Russia, the CIS and non-CIS countries in line with the best international practice. Member of the International Association of Universities.
The University engages in world-class basic and clinical research and fosters its commercialisation towards better patient and community health. It develops the unique clinical base of its own, provides highly qualified medical care in Russia using cutting-edge science and technology; it is an active contributor to the effective fight against dangerous diseases internationally.
It is currently listed in all international rankings of higher education institutions.
Rector of the I.M. Sechenov First Moscow State Medical University, Academician of the Russian Academy of Sciences, Professor Pyotr V. Glybochko.
About NANOLEK
NANOLEK is a rapidly growing forward-thinking Russia-based biopharmaceutical company with its own high-tech GMP and ISO-compliant full-cycle production facilities, targeted at import-substitution and innovative medicines, whether developed in-house or created with international partners, with a focus on the prevention and therapy of diseases of high social relevance. The Company is uniquely experienced in technology transfer via partnerships with the world’s leading pharmaceutical companies (Merck, Sanofi, Novartis, Egis, Celltrion, Riemser, etc.). Nanolek LLC was ranked first in the Fast Growing Large Companies category of the TEKHUSPEKH 2019 rating. Nanolek was even a participant in the Ministry of Economic Development’s priority project “Supporting Private High-Tech Companies Leaders” (“National Champions”) in 2017.
Today, the company is a leader in the production of paediatric vaccines in the Russian Federation. NANOLEK’s versatile product portfolio offers the following therapeutic areas: vaccines, HIV drugs, cancer drugs, etc.
On August 14, 2019, Nanolek LLC withdrew from ROSNANO’s list of portfolio companies.
In 2020, Nanolek LLC was added to the list of backbone enterprises of the Russian national economy. The decision to add the company to the list was made by a government commission on improving the sustainability of the Russian economy. The industry list was published on the website of the Russian Ministry of Industry and Trade on April 25, 2020.